Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS).  Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.

Biotechnology

Inhalon

John Whelan

Bill Picht

Brian Farrer

Jeff Hutchins

Thomas Moench

Sam Lai

The executive team at Inhalon has a history of experience in the pharmaceutical industry, with a focus on biotechnology. The team has held positions at various companies, including Neuraltus Pharmaceuticals, Heron Therapeutics, and Raven Biotechnologies. The team also has experience in academia, with members having taught at the University of North Carolina at Chapel Hill and the Johns Hopkins University.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Inhalon

Leadership Team

Board of Directors